Zhang, Haonan
Qiao, Anna
Yang, Linlin
Van Eps, Ned
Frederiksen, Klaus S.
Yang, Dehua
Dai, Antao
Cai, Xiaoqing
Zhang, Hui
Yi, Cuiying
Cao, Can
He, Lingli
Yang, Huaiyu
Lau, Jesper
Ernst, Oliver P.
Hanson, Michael A.
Stevens, Raymond C.
Wang, Ming-Wei
Reedtz-Runge, Steffen
Jiang, Hualiang
Zhao, Qiang
Wu, Beili
Article History
Received: 10 July 2017
Accepted: 20 November 2017
First Online: 4 January 2018
Competing interests
: K.S.F., J.L. and S.R.-R. are employees of Novo Nordisk, a pharmaceutical company focused on class B GPCRs for type 2 diabetes. R.C.S. is a founder and board member of Bird Rock Bio, a company focused on GPCR therapeutic antibodies. The remaining authors declare no competing financial interests.